NEWARK, Del, June 08, 2023 (GLOBE NEWSWIRE) -- The Small Molecule Innovator CDMO Market size is projected to be valued at US$ 48.09 billion in 2023 and is expected to rise to US$ 89.43 billion by 2033. The sales of small molecule innovator CDMO are expected to grow at a significant CAGR of 6.4% during the forecast period.
The small molecule innovator contract development and manufacturing organization (CDMO) market is a rapidly growing and dynamic sector that provides essential services to the pharmaceutical and biotech industries. The market is driven by the increasing demand for outsourcing drug development and manufacturing activities, as well as the growing complexity of drug molecules, which requires specialized expertise and equipment.
Get your PDF Sample Report with Latest Market Information @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16887
The majority of small molecule innovator CDMOs are concentrated in North America and Europe, with a few players in Asia. This is due to the concentration of the pharmaceutical industry in these regions, as well as the regulatory requirements for drug development and manufacturing. The small molecule innovator CDMO market is highly specialized, with players focusing on specific areas such as formulation development, API synthesis, and analytical testing. This allows them to develop deep expertise and offer high-quality services to their clients.
The small molecule innovator CDMO market is adopting new technologies such as continuous manufacturing and automation to increase efficiency and reduce costs. However, the adoption of these technologies is still in its early stages, and many players are still using traditional batch manufacturing methods. Overall, the small molecule innovator CDMO market is a rapidly growing and dynamic sector that provides essential services to the pharmaceutical and biotech industries.
The market is undergoing consolidation, and players are focusing on specialization and technology adoption to stay competitive.
Key Takeaways from this Market:
- The small molecule API segment is expected to record a swift growth of 6.7% during the forecast period. This expansion can be attributed primarily to regulatory agencies' high approval rate of NME small molecules.
- In 2022, the clinical stage segment held a sub-substantial share of the market, accounting for 55.1% of total revenue. During clinical procedures, CDMOs provide specialized expertise, time savings, and cost efficiency. This is expected to boost segmental growth during the forecast period.
- In terms of customer type, pharmaceutical companies had the controllable share (93.9%) in 2022. The growing emphasis on core competencies, such as sales, and the adoption of expansion strategies by CDMOs for manufacturing small molecule drugs, are driving the segment's market growth.
- The oncology segment acquired a prominent share of the market in 2022, accounting for 41.8% of revenue, and it is expected to grow at the fastest rate of more than 7.0% over the forecast period. One of the major factors supporting the segment's growth is the large number of oncology drugs in the regulatory approval pipeline.
- Over the forecast period, Asia Pacific is expected to record a healthy growth of 7.2% because of significantly lower manufacturing costs than in North America and Europe, as well as favorable regulations that encourage innovation
Ask our Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16887
Competitive Landscape:
The presence of numerous competitors in the market influences service pricing, making it a direct source of competition, especially for small-scale providers. To gain a competitive advantage, market vendors are expected to focus on providing one-stop-shop services. With access to significant capital, the CMO could engage in these activities, making entry difficult for new players and increasing competition. Partnerships, company expansions, innovations, and acquisitions are among the strategies used by market participants to improve their product offerings and gain a sustainable competitive advantage.
Latest Developments:
- Catalent announced in January 2023 that it had signed a development and license agreement with Ethicann Pharmaceuticals Inc., a Canadian/American specialty pharmaceutical company specializing in developing high-value cannabinoid drug therapies, to advance Ethicann's clinical drug pipeline using Zydis orally disintegrating tablet (ODT) technology.
- Binding Site Group, a global provider of speciality diagnostics, was acquired by Thermo Fisher Scientific Inc. for US$ 2.8 billion in January 2023. The Binding Site expands Thermo Fisher's already extensive specialized diagnostics range by adding ground-breaking innovation in multiple myeloma diagnosis and monitoring.
Key Companies Profiled:
- Piramal Pharma Solutions
- CordenPharma International
- Wuxi AppTec
- Cambrex Corporation
- Recipharm AB
- Pantheon (Thermo Fisher Scientific)
- Lonza
- Catalent Inc.
- Siegfried Holding AG
- Boehringer Ingelheim
- Labcorp Drug Development
Key Segments Covered in this Market Report:
- Product Outlook
- Small Molecule API
- Small Molecule Drug Product
- Oral solid dose
- Semi-Solid Dose
- Liquid Dose
- Others
Stage Type Outlook:
- Preclinical
- Clinical
- Phase I
- Small
- Medium
- Large
- Phase II
- Small
- Medium
- Large
- Phase III
- Small
- Medium
- Large
- Commercial
Customer Type Outlook:
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
Therapeutic Area Outlook:
- Cardiovascular disease
- Oncology
- Respiratory disorders
- Neurology
- Metabolic disorders
- Infectious disease
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan (APEJ)
- Japan
- Middle East & Africa (MEA)
For more Report Customization, connect with us at https://www.futuremarketinsights.com/customization-available/rep-gb-16887
Table of Content (ToC):
1. Executive Summary | Small Molecule Innovator CDMO Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
Request a Complete TOC of this Report with figures @ https://www.futuremarketinsights.com/toc/rep-gb-16887
Explore FMI’s related ongoing Coverage in Healthcare Market Domain:
Small Molecule API Market Size: Global demand for Small Molecule API is expected to rise at a yearly growth rate of 5.0% Y-o-Y to US$ 216.97 Billion in 2032
RNA-Targeted Small Molecules Market Share: According to the latest research by Future Market Insights, the RNA-Targeted Small Molecules market is set to witness a 6.6% growth during the year 2021 to 2031.
Large Molecule Bioanalytical Testing Services Market Growth: Newly-released Large Molecule Bioanalytical Testing Service is projected to reach US$ 4.7 Billion by 2033. The clinical Phase is expected to generate significant revenue and is projected to grow at a CAGR of 10.9% from 2023 to 2033.
Pharmacy Refrigerators Market Demand: The global pharmacy refrigerators market is estimated to be valued at US$ 552.3 million in 2022, rising to US$ 1,027 million by 2032 with a CAGR of 5.8% during the forecast period.
Global IV Disposables Market Opportunity: According to Future Market Insights research, during the projected period, the global IV disposables market is expected to grow at a CAGR of 11.8%. The market value is projected to increase from US$ 17.0 Billion in 2023 to US$ 51.6 Billion by 2033.
Global CMO/CDMO Market Development: The global CMO/CDMO market is estimated to be valued at US$ 22.5 billion in 2023. The market is projected to reach US$ 39.4 billion by 2033, exhibiting a CAGR of 5.7% from 2023 to 2033.
Digital Psychotherapeutics Market Strategies: The global digital psychotherapeutics market size is projected to be worth US$ 1.06 billion in 2023. Over the next ten years, global digital psychotherapeutics demand is likely to accelerate at 27.6% CAGR. By 2033, the total market value is expected to surpass US$ 12.2 billion.
Clinical Research Organization Market Trends: According to Future Market Insights (FMI) analysis in a recent market survey, the global clinical research organization market was valued at US$ 58.0 Billion in 2022 and is expected to reach US$ 139.6 Billion by 2033.
Mastectomy Reconstruction Implants Market Outlook: According to Future Market Insights (FMI) analysis in a recent market survey, the global mastectomy reconstruction implants market was valued at US$ 1.95 Billion in 2022 and is set to reach US$ 4.69 Billion by 2033.
Pulmonology Devices Market Forecast: The global pulmonology devices market is estimated at US$ 1.4 billion in 2023. The market is projected to reach US$ 3.8 billion by 2033, exhibiting a CAGR of 10.3% from 2023 to 2033.
About Future Market Insights (FMI):
Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blogs
